Gilead Sciences Inc. (GILD)

72.85
NASDAQ : Health Technology
Prev Close 73.86
Day Low/High 71.91 / 75.39
52 Wk Low/High 60.89 / 85.97
Avg Volume 18.76M
Exchange NASDAQ
Shares Outstanding 1.26B
Market Cap 88.02B
EPS 4.20
P/E Ratio 17.50
Div & Yield 2.72 (3.62%)

Latest News

Licking Our Wounds and Waiting to See How the Covid-19 Story Plays Out

Licking Our Wounds and Waiting to See How the Covid-19 Story Plays Out

The next four to six weeks could determine whether the U.S. economy can recover from the coronavirus crisis without lasting damage

Mild Good News as Japanese Flu Drug Shows Promise in Mild Covid-19 Cases

Mild Good News as Japanese Flu Drug Shows Promise in Mild Covid-19 Cases

Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.

Keeping Sane, the Profitable Way: How I'm Playing This Market

Keeping Sane, the Profitable Way: How I'm Playing This Market

I continue to shuttle new money into the market on declines using buy-write option strategies.

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.

These Are the Times We Live In

These Are the Times We Live In

Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.

Gilead Raised to Buy at DZ Bank

The Magic Mice of Regeneron

The Magic Mice of Regeneron

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

Volatility Yes, but There's Positive News Too

The market has gained some momentum. It looks like the administration might be readying to declare a national emergency. The president is scheduled to make comments starting an hour before the market close. I expect equities to continue to be volati...

5 Leading Biotechs in Search of a Coronavirus Vaccine

5 Leading Biotechs in Search of a Coronavirus Vaccine

The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.

Early Rebound

Markets look like they will see a substantial rebound today, at least in the early going. S&P 500 futures are up some 5% just before the market opens. Gilead Sciences  just reported encouraging results around its experimental antiviral Remdesivir in...

Will Gilead Sciences Remdesivir Help Arrest the Coronavirus?

Will Gilead Sciences Remdesivir Help Arrest the Coronavirus?

Right now, GILD holds a strictly defensive spot among my holdings.

Coronavirus Impact Spreads, Market Selloff, Fed Action, Risk Tolerance

Coronavirus Impact Spreads, Market Selloff, Fed Action, Risk Tolerance

What came first? The chicken or the egg? The bear market or the pandemic? I don't care much for labels.

Don't Do the Coronavirus Chase

Don't Do the Coronavirus Chase

There are small vaccine and testing companies that see their shares spike when a new virus hits, but whether those gains will last is questionable.

The Oil Factor, 50 Year Bonds, Trading Clorox and Gilead Sciences: Market Recon

The Oil Factor, 50 Year Bonds, Trading Clorox and Gilead Sciences: Market Recon

The question begs... 'Do significantly lower oil prices provoke increased demand?' Anywhere?

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Roller Coaster Markets, Time for Emergency Measures, 3 Stock Groups to Focus On

Roller Coaster Markets, Time for Emergency Measures, 3 Stock Groups to Focus On

I'll stick to the three-pronged approach... the Rebound group, the Virus group, and the Revenue group.

Gilead Cut at DZ Bank

Market Outflows, Unknown Earnings Expectations and Trading Notes: Market Recon

Market Outflows, Unknown Earnings Expectations and Trading Notes: Market Recon

Here are a number of things that I'm watching now.

Playing the Hand You're Dealt

Playing the Hand You're Dealt

Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.

Jim Cramer: We're Not Yet Inured to Coronavirus Disappointment

Jim Cramer: We're Not Yet Inured to Coronavirus Disappointment

Microsoft says it will miss its personal computer forecast, but Marriott appears to be trading up a tad.

Moderna Could Spike Much Higher as the Pandemic Story Plays Out

Moderna Could Spike Much Higher as the Pandemic Story Plays Out

Hot money will be attracted to stocks that show promise in dealing with the coronavirus.

Jim Cramer: 3 Market Storylines Are In Play, But Which Is Best for Investors?

Jim Cramer: 3 Market Storylines Are In Play, But Which Is Best for Investors?

Only one of these scenarios is going to get you in and out of this market with your assets intact and your portfolio stronger.

Jim Cramer: Hope for the Best, Plan for the Worst

Jim Cramer: Hope for the Best, Plan for the Worst

Is this the end of the world? No. You still need to plan for your financial well-being, even as the CDC tells us 'this might be bad.'

Jim Cramer: Want the Bulls' Biggest Nightmare? Here It Is

Jim Cramer: Want the Bulls' Biggest Nightmare? Here It Is

This entirely logical scenario would pull the rug out from under the bull market.

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

Gilead Gets Some Serious Play

Gilead Gets Some Serious Play

I wouldn't be a buyer of Gilead on the coronavirus news, I'd be a buyer because the yield and chart look pretty darn good.

Gilead Has Become and Will Be a Volatile Name

Gilead Has Become and Will Be a Volatile Name

I would consider any entry a trade, and not an investment.

Shares of Gilead Could Surge to the $88 Area in the Near-Term

Shares of Gilead Could Surge to the $88 Area in the Near-Term

Any modest intraday dip is probably a buying opportunity.